Innovent Biologics Inc., a leading biopharmaceutical company, released its 2024 Annual Report, highlighting significant business updates and financial performance. The company reported a 51.8% increase in revenue, reaching RMB 9,421,888,000, and a gross profit of RMB 7,911,678,000, marking a 56.1% rise compared to the previous year. Innovent achieved profitability with a loss reduction of 90.8% year-over-year, posting a loss of RMB 94,631,000 for the year. Notably, the company recorded a Non-IFRS profit of RMB 331,611,000, a turnaround from the previous year's loss. The year 2024 marked historic milestones for Innovent, with record-high revenue and an expanded product portfolio of 15 approved products. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.